Edgewise Therapeutics, Inc. — Q1 2021 Form 10-Q
Business context and reporting period. The clinical-stage biopharmaceutical company reported for the three months ended March 31, 2021. It is developing treatments for rare muscle disorders; lead candidate EDG-5506 was in a Phase 1 trial, while its other programs remained in research or preclinical development. The company had no approved products and generated no revenue.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / prior year-end |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.36 million | $2.97 million |
| General and administrative expense | $1.50 million | $0.28 million |
| Net loss | $6.82 million | $3.19 million |
| Net loss per share, basic and diluted | $4.37 | $7.57 |
| Operating cash used | $6.06 million | $2.74 million |
| Cash and cash equivalents | $221.04 million | $104.92 million at Dec. 31, 2020 |
| Marketable securities | $88.84 million | $24.18 million at Dec. 31, 2020 |
| Total assets | $311.25 million | $131.14 million at Dec. 31, 2020 |
| Current liabilities | $4.85 million | $4.34 million at Dec. 31, 2020 |
| Debt | None outstanding | — |
Margins are not meaningful because the company had no revenue. Cash, cash equivalents and marketable securities totaled approximately $309.9 million at quarter-end. Investing cash outflow was $64.8 million, mainly purchases of marketable securities; financing cash inflow was $187.0 million, primarily from the IPO. The accumulated deficit was $41.0 million.
Material changes and unusual items
- R&D expense rose $2.39 million year over year, reflecting higher EDG-5506 clinical-trial costs, increased discovery and preclinical work, and greater employee costs.
- G&A expense increased $1.22 million, principally from additional personnel and professional and consulting costs.
- The company completed its IPO on March 30, issuing 12.65 million shares at $16 per share. Net proceeds were approximately $186.1 million after underwriting discounts, commissions and offering costs. Outstanding preferred stock converted into common stock; the company also effected a 1-for-1.8932 reverse stock split.
- Quarter-end common shares outstanding were 49.25 million. The reported loss per share is not directly comparable across periods given the substantial change in share count and capital structure.
- Unrealized losses on available-for-sale securities were $54,000. No material legal proceedings were reported.
Outlook, commentary and risks
- Management expects operating expenses, particularly R&D, to increase as EDG-5506 advances and additional programs and public-company needs are funded. The company expects continued losses and has not provided revenue guidance.
- The MD&A says available cash and securities are expected to fund the planned operating plan for at least 24 months. The liquidity note, however, says they are expected to meet needs through at least the next 12 months; this difference should be checked against the filed statements and subsequent disclosures.
- COVID-19 disrupted productivity, clinical-trial operations and enrollment, data collection, and supply-chain activities. The company warned that further disruptions could delay development and regulatory timelines or increase costs.
- EDG-5506 is early-stage and its safety and efficacy remain uncertain. The filing reports dose-limiting somnolence at the 135 mg level in a single-ascending-dose trial.
- The company relies on third parties for clinical work and manufacturing; it had switched EDG-5506 manufacturing to a U.S. supplier and disclosed no alternative manufacturer in place. Other key risks include clinical and regulatory failure, financing needs, competition, and intellectual-property uncertainty. The company stated that its patent portfolio was pending prosecution and that it did not own or in-license issued patents at the time.
- Potential OSIF license payments include up to $1.3 million per covered product for development and regulatory milestones, approximately $2.3 million per product for sales milestones, and low-single-digit royalties on net sales. These are contingent obligations, not current fixed payments.
Important facts for investors to verify
- Clarify the filing’s 12-month versus 24-month cash-runway statements and review subsequent cash use and financing.
- Track EDG-5506 trial progress, enrollment and safety findings, including follow-up on somnolence, and verify all trial data against final reported results.
- Monitor R&D spending, cash burn and the timing and cost of advancing other programs.
- Assess manufacturing continuity, COVID-related trial or supply impacts, and the status and scope of patent applications and third-party rights.
- Review the contingent OSIF license terms and any future milestone, royalty or sublicense obligations.